Following EMA, FDA restricts use of high-dose Xeljanz, warning of added risks for the blockbuster JAK

The FDA has come out with new restrictions on the use of Pfizer’s high-dose version of Xeljanz after researchers drew a direct line between the 10 mg dose and a higher risk of blood clots and death.